

Quarterly Results announcement form

Name of listed company : SIIC Medical Science and Technology (Group) Limited

Stock code : 8018

Year end date : 31/12/2000

Important Note :

This result announcement form only contains extracted information from and should be read in conjunction with the detailed results announcement of the issuer, which can be viewed on the GEM website at <http://www.hkgem.com>

	(Unaudited) Consolidated	(Unaudited) Proforma combined
	Current Period from <u>01/01/2000</u> to <u>31/03/2000</u>	Last Corresponding Period from <u>01/01/1999</u> to <u>31/03/1999</u>
	HK\$'000	HK\$'000
Turnover		
- Continuing	127,670	88,688
- Discontinued	0	0
Operating Profit/(Loss)		
- Continuing	25,627	21,444
- Discontinued	0	0
Total Operating Profit/(Loss)	25,627	21,444
Share of Profit/(Loss) of Associated Companies	0	0
Share of Profit/(Loss) of Jointly Controlled Entities	946	782
Profit/(Loss) after Taxation & MI	13,546	11,049
% Change Over the Last Period	22.60	%
EPS / (LPS) - Basic	2.2 cents	N/A
- Diluted	N/A	N/A
Extraordinary (ETD) Gain/(Loss)	0	0
Profit (Loss) after ETD Items	13,546	11,049
Interim Dividend per Share (specify if with other options)	NIL	NIL
B/C Dates for Interim Dividend Payable Date	N/A	N/A
B/C Dates for AGM/SGM	N/A	N/A
Other Distribution for Current Period	NIL	NIL
B/C Dates for Other Distribution	N/A	N/A
* Please delete as appropriate		(bdi: both days inclusive)

Remarks :

1. Basis of preparation

The Company was incorporated in the Cayman Islands on 17th September, 1999 under the Companies Law (1998 Revision) of the Cayman Islands and the re-organization of the Group prior to the listing on GEM of The Stock Exchange of Hong Kong Limited was completed in November 1999, as such the results under the consolidated basis only reflect the actual results for the period from 1st January, 2000 to 31st March, 2000. The pro forma combined results for the three months ended 31st March, 1999, which are provided for information purpose only, have been prepared on a basis as if the current group structure had been in existence since 1st January, 1999.

2. Turnover

Turnover represents the net amounts received and receivable for goods sold by the Group to outside customers during the period.

3. Income tax expenses

	Three months ended 31st March	
	2000	1999
	Consolidated	Proforma Combined
	HK\$'000	HK\$'000
The charge comprises:		
PRC income tax	4,024	2,710
Share of PRC income tax of a jointly controlled entity	135	54
	4,159	2,764

Pursuant to the relevant laws and regulations in the mainland PRC, the Group's PRC subsidiary and jointly controlled entity are entitled to exemption from PRC income tax for two years commencing from their first profit-making year of operation and thereafter, they are entitled to a 50% relief from PRC income tax for the following three years.

The tax holiday for Chia Tai Qingchunbao Pharmaceutical Co., Ltd. ("Hangzhou Qingchunbao") has expired. However, pursuant to an approval received from local tax authorities on 16th September, 1998, Hangzhou Qingchunbao was classified as one of the approved "High Technology entities". Accordingly, Hangzhou Qingchunbao is entitled to a preferential PRC income tax rate of 12% for the three years ending 31st December, 2000.

During the period, the jointly controlled entity was in its fifth profitable year and was entitled to a 50% relief from PRC income tax at the applicable tax rate of 27%. Its subsidiaries are, however, subject to PRC income tax calculated at 33%.

The Group had no significant unprovided deferred taxation for the period.

4. Earnings per share

The calculation of the basis earnings per share is based on the profit for the period of HK\$13,546,000 and the weighted average of 620,000,000 shares in issue during the period. The earnings per share in respect of the three months ended 31st March, 1999 is not applicable as the Directors considered that the information is not relevant.

For and on behalf of
SIIC Medical Science and Technology (Group) Limited

Signature :

Name : Wong Mei Ling, Marina

Title : Company Secretary

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this results announcement form (the "Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information are accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make the Information herein inaccurate or misleading. The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.